Toxicoproteomics: New paradigms in toxicology research

Toxicology Mechanisms and Methods

Volumn 20, Issue 7, 2010, Pages 415-423

  George, Jasmine ^a   Singh, Richa ^a   Mahmood, Zafar ^a   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

2 Dimensional gel electrophoresis; Biomarker; Mass spectrometry; Toxicity; Toxicoproteomics

Indexed keywords

ARTICLE; CARDIOTOXICITY; ENVIRONMENTAL EXPOSURE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEOMICS; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SKIN TOXICITY; TOXICITY TESTING; TOXICOPROTEOMICS;

ANIMALS; BIOLOGICAL MARKERS; GENOME, HUMAN; HUMANS; PROTEOMICS; TISSUE DISTRIBUTION; TOXICOLOGY; XENOBIOTICS;

EID: 77955895075     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376511003667842     Document Type: Article

References (83)

1. Alderton PM, Gross J, Green MD. 1992. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529). Cancer Res 52:194-201.
2. Anderson NG, Anderson NL. 1996. Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis 17:443-453.
3. Anderson NL, Anderson NG. 2002. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 11:845-867.
4. Badghisi H, Liebler DC. 2002. Sequence mapping of epoxide adducts in human hemoglobin with LC-tandem MS and the SALSA algorithm. Chem Res Toxicol 15:799-805.
5. Bajzer Z, Randic M, Plavsic D, Basak SC. 2003. Novel map descriptors for characterization of toxic effects in proteomics maps. J Mol Graph Model 22:1-9.
6. Bandara L.R., Kennedy S. 2002. Toxicoproteomics-a new preclinical tool. Drug Discov Today 7:411-418.
7. Bandara LR, Kelly MD, Lock EA, Kennedy S. 2003a. A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol Sci 73:195-206.
8. Bandara LR, Kelly MD, Lock EA, Kennedy S. 2003b. A potential biomarker of kidney damage identified by proteomics: preliminary findings. Biomarkers 8:272-286.
9. Barber DS, Stevens S, LoPachin RM. 2007. Proteomic analysis of rat striatal synaptosomes during acrylamide intoxication at a low dose rate. Toxicol Sci 1:156-167.
10. Bristow MR, Mason JW, Billingham ME, Daniels SR. 1981. Dose effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709-718.
11. Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. 2006. Pesticides and Parkinson's disease-is there a link? Environ Health Perspect 114:156-164.
12. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. 2003. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394-1401.
13. Charlwood J, Skehel JM, King N, Camilleri P, Lord P, Bugelski P, Atif U. 2002. Proteomic analysis of rat kidney cortex following treatment with gentamicin. J Proteome Res 1:73-82.
14. Chen X, Ma XM, Ma SW, Coenraads PJ, Zhang CM, Liu J, Zhao LJ, Sun M, Tang NJ. 2009. Proteomic analysis of the rat ovary following chronic lowdose exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). J Toxicol Environ Health A 11:717-726.
15. Colquhoun DR, Goldman LR, Cole RN, Gucek M, Mansharamani M, Witter FR, Apelberg BJ, Halden RU. 2009. Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environ Health Perspect 7:832-838.
16. Conrad DH, Goyette J, Thomas PS. 2008. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23(Suppl. 1):78-84.
17. Cook-Bruns N. 2001. Retrospective analysis of the safety of herceptinR immunotherapy in metastatic breast cancer. Oncology 61:58-66.
18. Cutler P, Bell DJ, Birrell HC, Connelly JC, Connor SC, Holmes E, Mitchell BC, Monte SY, Neville BA, Pickford R, Polley S, Schneider K, Skehel JM. 1999. An integrated proteomic approach to studying glomerular nephrotoxicity. Electrophoresis 20:3647-3658.
19. Dapas B, Tell G, Scaloni A, Pines A, Ferrara L, Quadrifoglio F, Scaggiante B. 2003. Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur J Biochem 270:3251-3262.
20. Davis JW, Kramer JA. 2006. Genomic-based biomarkers of drug induces nephrotoxicty. Expert Opin Drug Meta Toxicol 2:95-101.
21. Dooley GP, Reardon KF, Prenni JE, Tjalkens RB, Legare ME, Foradori CD, Tessari JE, Hanneman WH. 2008. Proteomic analysis of diaminochlorotriazine adducts in wistar rat pituitary glands and LbetaT2 rat pituitary cells. Chem Res Toxicol 4:844-851.
22. Drake MG, Witzmann FA, Hyde J, Witten ML. 2003. JP-8 jet fuel exposure alters protein expression in the lung. Toxicology 191:199-210.
23. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. 1999. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26 (suppl. 12):96-101.
24. Fennell TR, Snyder RW, Krol WL, Sumner SC. 2003. Comparison of the hemoglobin adducts formed by administration of Nmethylolacrylamide and acrylamide to rats. Toxicol Sci 71:164-175.
25. Fessler MB, Malcolm KC, Duncan MW, Worthen GS. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. J Biol Chem 277:31291-31302.
26. Fletcher ST, Basketter DA. 2006. Proteomic analysis of the response of EpiDerm cultures to sodium lauryl sulphate. Toxicol In Vitro 20:975-985.
27. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L. 2000. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 11:2148-2161.
28. Gao J, Ann Garulacan L, Storm SM, Hefta SA, Opiteck GJ, Lin JH, Moulin F, Dambach DM. 2004. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol In Vitro 18:533-541.
29. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350.
30. Greene ND, Bamidele A, Choy M, de Castro SC, Wait R, Leung KY, Begum S, Gadian DG, Scott RC, Lythgoe MF. 2007. Proteome changes associated with hippocampal MRI abnormalities in the lithium pilocarpine-induced model of convulsive status epilepticus. Proteomics 8:1336-1344.
31. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. 1998. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28.
32. Heijne WH, Stierum RH, Slijper M, van Bladeren PJ, van Ommen B. 2003. Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. Biochem Pharmacol 65:857-875.
33. Heinke MY, Wheeler CH, Chang D, Einstein R, Drake-Holland A, Dunn MJ, dos Remedios CG. 1998. Protein changes observed in pacing-induced heart failure using two-dimensional electrophoresis. Electrophoresis 19:2021-2030.
34. Herman EH, Ferrans VJ. 1998. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 25(Suppl 10):15-21.
35. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J, Ferrans VJ. 2001. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48:297-304.
36. Hobson DJ, Rupa P, Diaz GJ, Zhang H, Yang M, Mine Y, Turner PV, Kirby GM. 2007. Proteomic analysis of ovomucoid hypersensitivity in mice by two-dimensional difference gel electrophoresis (2D-DIGE). Food Chem Toxicol 45:2372-2380.
37. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. 2003. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam andWyeth-14,643. Carcinogenesis 24:757-770.
38. Ishimura R, Ohsako S, Kawakami T, Sakaue M, Aoki Y, Tohyama C. 2002. Altered protein profile and possible hypoxia in the placenta of 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed rats. Toxicol Appl Pharmacol 185:197-206.
39. Izzotti A, Bagnasco M, Cartiglia C, Longobardi M, De Flora S. 2004. Proteomic analysis as related to transcriptome data in the lung of chromium(VI)-treated rats. Int J Oncol 24:1513-1522.
40. Jain KK. 2004. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5:331-336.
41. Janech MG, Raymond JR, Arthur JM. 2007. Proteomics In renal research. Am J Physiol Renal Physiol 292:F501-F512.
42. Jeon JP, Buono RJ, Han BG, Jang EY, Kim SC, Yang CH, Hwang MJ. 2008. Proteomic and behavioral analysis of response to isoliquiritigenin in brains of acute cocaine treated rats. Proteome Res 12:5094-5102.
43. Joo WA, Kang MJ, Son WK, Lee HJ, Lee DY, Lee E, Kim CW. 2003. Monitoring protein expression by proteomics: human plasma exposed to benzene. Proteomics 3:2402-2411.
44. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y. 2005. A comprehensive listing of bioactivation pathways of organic finctional groups. Curr Drug Metab 6:161-225.
45. Kang YJ. 2001. Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect 109:27-34.
46. Kaplowitz N. 2004. Drug-induced liver injury. Clin Infect Dis 2:S44-S48.
47. Kennedy S. 2001. Proteomics profiling from human samples: the body fluid alternative. Toxicol Lett 120:379-384.
48. Kim MR, Kim CW. 2006. Human blood plasma preparation for two-dimensional gel electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 849:203-210.
49. Labban NG. 1982. The nature of Langerhans cells granules: an ultrastructural study. Histopathology 6:317-325.
50. Lambertenghi-Deliliers G, Zanon PL, Pozzoli EF, Bellini O. 1976. Myocardial injury induced by a single dose of adriamycin: an electron microscopic study. Tumor 62:517-528.
51. Lauber WM, Carroll JA, Dufield DR, Kiesel JR, Radabaugh MR, Malone JP. 2001. Mass spectrometry compatibility of two-dimensional gel protein stains. Electrophoresis 22:906-918.
52. Macdonald N, Chevalier S, Tonge R, Davison M, Rowlinson R, Young J, Rayner S, Roberts R. 2001. Quantitative proteomic analysis of mouse liver response to the peroxisome proliferator diethylhexylphthalate (DEHP). Arch Toxicol 75:415-424.
53. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. 2005. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta r. Ann NY Acad Sci 1053:356-375.
54. Marengo E, Robotti E, Gianotti V, Righetti PG, Cecconi D, Domenici E. 2003. A new integrated statistical approach to the diagnostic use of two-dimensional maps. Electrophoresis 24:225-236.
55. Mauri P, Scigelova M. 2009. Multidimensional protein identification technology for clinical proteomic analysis. Clin Chem Lab Med 47:636-646.
56. Merrick BA. 2009. The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Brief Funct Genomic Proteomic 7:35-49.
57. Oberemm A, Meckert C, Brandenburger L, Herzig A, Lindner Y, Kalenberg K, Krause E, Ittrich C, Kopp-Schneider A, Stahlmann R, Richter-Reichhelm HB, Gundert-Remy U. 2005. Differential signatures of protein expression in marmoset liver and thymus induced by single-dose TCDD treatment. Toxicology 206:33-48.
58. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik YK, Yoo JS, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X, Zeng R, Archakov A, Tsugita A, Beer I, Pandey A, Pisano M, Andrews P, Tammen H, Speicher DW, Hanash SM. 2005. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 13:3226-3245.
59. Pai VB, Nahata MC. 2000. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263-302.
60. Pan TL, Wang PW, Huang CM, Chen CC, Fang JY. 2009. Elucidation of the percutaneous absorption of chromium compounds by functional proteomics. Proteomics [epub: Ahead of print]
61. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. 2005. The role of metabolic activation in drug-induced heaptotoxicity. Annu Rev Pharmacol Toxicol 45:117-202.
62. Park BK, Kitteringham NR, Powell H, Pirmohamed M. 2000. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 153:39-60.
63. Patel S, Sinha A, Singh MP. 2007. Identification of differentially expressed proteins in striatum of maneb-and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol Teratol 5:578-585.
64. Petricoin EF, Rajapaske V, Herman EH, Arekani AM, Ross S, Johann D, Zhang AKJ, Hitt BH, Conrads TP, Veenstra TD, Liotta LA, Sistare FD. 2004. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection, Toxicol Pathol 32(Suppl. 1):122-130.
65. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. 2003. Multicomponent immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 3:422-432.
66. Qian WJ, Goshe MB, Camp DG 2nd, Yu LR, Tang K, Smith RD. 2003. Phosphoprotein isotope-coded solid-phase tag approach for enrichment and quantitative analysis of phosphopeptides from complex mixtures. Anal Chem 75:5441-5450.
67. Righetti PG, Castagna A, Antonucci F. 2004. Critical survey of quantitative proteomics in two-dimensional electrophoretic approaches. J Chromatogr A 1051:3-17.
68. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. 2002. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65:135-150.
69. Sarioglu H, Brandner S, Haberger M, Jacobsen C, Lichtmannegger J, Wormke M, Andrae U. 2008. Analysis of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced proteome changes in 5L rat hepatoma cells reveals novel targets of dioxin action including the mitochondrial apoptosis regulator VDAC2. Mol Cell Proteom 7:394-410.
70. Scheler C, Müller EC, Stahl J, Müller-Werdan U, Salnikow J, Jungblut P. 1997. Identification and characterisation of heat shock protein 27 species in human myocardial two-dimensional electrophoresis patterns. Electrophoresis 18:2823-2831.
71. Son WK, Lee DY, Lee SH, Joo WA, Kim CW. 2003. Analysis of proteins expressed in rat plasma exposed to dioxin using 2-dimensional gel electrophoresis. Proteomics 3:2393-2401.
72. Steiner G, Suter L, Boess F, Gasser R, de Vera MC, Albertini S, Ruepp S. 2004. Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 112:1236-1248.
73. Thome-Kromer B, Bonk I, Klatt M, Nebrich G, Taufmann M, Bryant S, Wacker U, Kopke A. 2003. Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics 3:1835-1862.
74. Van Laar VS, Dukes AA, Cascio M, Hastings TG. 2008. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis 3:477-489.
75. Wetmore BA, Merrick BA. 2004. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol 6:619-642.
76. Wittmann-Liebold B, Graack HR, Pohl T. 2006. Two-dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 6:4688-4703.
77. Witzmann FA, Li J. 2004. Proteomics and nephrotoxicity. Contrib Nephrol 141:104-123.
78. Wojtacki J, Lewicka-Nowak E, Leniewski-Kmak K. 2000. Anthracycline- induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention-review of the literature. Med Sci Monit 6:411-420.
79. Woosley RL, Chen Y, Freiman JP, Gillis RA. 1993. Mechanism of the cardiotoxic actions of tefenadine. J Am Med Assoc 269:1532-1536.
80. Yates JR. 2004. Mass spectral analysis in proteomics. Annu Rev Biophys Biomol Struct 33:297-316.
81. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K. 2005. Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev 5:707-714.
82. Zhang J, Herman EH, Ferrans VJ. 1993. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 142:1916-1926.
83. Zhang J, Herman EH, Knapton A, Chadwick DP, Whitehurst VE, Koerner JE, Papoian T, Ferrans VJ, Sistare FD. 2002. SK&F 95654-Induced acute cardiovascular toxicity in Sprague-Dawley rats-histopathologic, electron microscopic, and immunohistochemical studies. Toxicol Pathol 30:28-40.